Anti-aging therapy for canines and other domesticated animals

Patent metadata

Field	Value
Publication number	US-12201589-B2
Application number	US-202217676486-A
Country	US
Kind code	B2
Filing date	Feb 21, 2022
Priority date	Apr 12, 2018
Publication date	Jan 21, 2025
Grant date	Jan 21, 2025

Abstract

The present invention discloses a system and method for improving the quality of life in canines and other domesticated animals. As animals age testosterone and other supportive hormones diminish causing reduced activity, a lack of mobility, decreased bone density, and general well-being. Precursor compositions are selected and designed for the purpose of formulating non-toxic therapeutic hormone supplements for oral consumption. The process and method of this invention is comprised of therapies produced from two or more selected non-toxic prohormones that combine during digestion and delivered through a chewable and edible gummy treat. As such there is no requirement for changing the subject's current diet. The present invention features a continuous low dose supplementation to be incorporated daily whereby dosages are correlated according to the subject's age, weight, sex, and breed. The beneficial results of the present invention are achieved through the absorption of the prohormones in the composition into the bloodstream effecting delivery to all cells including those specific cells where the conversion enzymes are activated by the organism's needs. The delivery and transport of inactive prohormones minimizes liver toxicity since the precursors are carried through the hepatic portal system to and through the liver and into general circulation in inactive forms.

First claim

The invention claimed is:

1. A composition comprising a first and a second androgenic prohormone wherein at least one of said first and said second androgenic prohormone is selected from the group consisting of: DHEA, 7-keto DHEA, pregnenolone, androstenedione, androstenediol, and DHEA-S.

2. The composition of claim 1 wherein at least one of said first and said second androgenic prohormone is selected from the group consisting of: DHEA, 7-keto DHEA, and DHEA-S.

3. The composition of claim 1 further comprising an oil selected from the group consisting of: vegetable, rapeseed/canola, soy, corn, peppermint, lavender, sandalwood, bergamot, rose, chamomile, ylang-ylang, tea tree, myrcene/hops, jasmine, and lemon.

4. The composition of claim 1 further comprising nutmeg or nutmeg extract.

5. The composition of claim 1 formulated as an oral preparation formulated as a chewable edible treat.

6. The composition of claim 1 formulated as an oral preparation selected from the group consisting of: an animal feed, a food supplement, a prescription food product, a spray, an ampule, a supplemented rawhide, a vitamin D supplement, and a chew toy.

7. The composition of claim 1 formulated as a feed supplement, said supplement in a format selected from the group consisting of: a gel, a powder, a liquid, a grating, a strip, an ampule, a tablet, and a capsule.

8. A composition comprising a first and a second androgenic prohormone further comprising a compound that binds and stimulates a mammalian endocannabinoid receptor.

9. The composition of claim 8 wherein DHEA-S at least one of said first and said second androgenic prohormone comprises DHEA-S.

10. The composition of claim 8 wherein said endogenous endocannabinoid receptor is selected from the group consisting of: CB1, CB2, TRPV1, TRPV2, TRPV3, TRPV4, TRPA1, TRPM8, GPR18, GPR119, GPR55, GPR118 and analogues thereto.

11. The composition of claim 10 wherein said compound that binds and stimulates a mammalian endocannabinoid receptor comprises a member of a class selected from the group consisting of: cannabigerol class, cannabichromene class, cannabicyclol class, Δ 8 -tetrahydrocannabinol class, cannabieson class, cannabinol and cannabinodiol class, cannabitriol class, and miscellaneous class.

12. The composition of claim 11 wherein said compound that binds and stimulates a mammalian endocannabinoid receptor comprises a member of the cannabinol and cannabinodiol class.

13. The composition of claim 11 wherein said compound that binds and stimulates a mammalian endocannabinoid receptor comprises a member of the Cannabichromene class.

14. The composition of claim 8 wherein said compound that binds and stimulates a mammalian endocannabinoid receptor comprises a compound selected from the group consisting of: cannabidiolic acid (CBDA), cannabidiol (CBD), cannabidiol monomethylether (CBDM), cannabidiol C4 (CBD-C4), and cannabidivarinic acid (CBDVA).

15. A method for providing a safe therapeutic composition to a canine, said method comprising delivering to a canine a composition comprising a first and a second androgenic prohormone wherein at least one of said first and said second androgenic prohormone is selected from the group consisting of: DHEA, 7-keto DHEA, pregnenolone, androstenedione, androstenediol, and DHEA-S.

16. The method of claim 15 wherein said composition is delivered in the format of a chewable edible treat.

17. The method of claim 15 that results in slowing or reversing one or more health declines associated with aging.

18. The method of claim 17 wherein said one or more health declines is selected from the group consisting of: increased obesity, arthritis, reduced bone density, cardiomyopathy, joint dysplasia, diabetes, blindness, and gum disease.

19. The method of claim 15 wherein said canine comprises a hepatic portal system and a liver wherein the hepatic portal system carries prohormone in said composition safely through the liver to systemic circulation.

Assignees

• Postrel Richard

Inventors

• Postrel Richard

Classifications

• A61K36/3482

  Cannabis · CPC title

• A61K36/3486

  Humulus · CPC title

• A61K36/185

  Magnoliopsida (dicotyledons) · CPC title

• A61K31/658 Primary

  o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol · CPC title

• A23K20/184

  Hormones · CPC title